scholarly journals PD-L1/PD-1 Expression in Endometrial Clear Cell Carcinoma: A Potential Surrogate Marker for Clinical Trials

2019 ◽  
Vol 28 (1) ◽  
pp. 31-37
Author(s):  
Cao Jin ◽  
Sean Hacking ◽  
Sharon Liang ◽  
Mansoor Nasim
Keyword(s):  
Cell Carcinoma ◽  
Clear Cell ◽  
Clear Cell Carcinoma ◽  
Surrogate Marker ◽  
Myometrial Invasion ◽  
Lymphocyte Infiltration ◽  
Pathological Features ◽  
Napsin A ◽  
Programmed Death ◽  
Clinical And Pathological Features

Background. Endometrial clear cell carcinoma (ECCC) represents a rare subtype of endometrial cancer. Recently, immunotherapeutic drugs targeting programmed cell death protein 1 (PD-1)/programmed death ligand-1 (PD-L1) was associated with improved survival in several types of cancer (especially in patients with mismatch-repair (MMR)-deficient status). The aim of this study is to evaluate the correlation between the PD-L1/PD-1 axis and clinical and pathological features in strictly defined ECCC diagnosed at our institution. Design. Review of ECCC (diagnosed in the period of 2000 to 2017) identified 23 cases (n = 23) in our institution. The cases were reviewed by 2 gynecological pathologists. Estrogen receptor, progesterone receptor, napsin A, p16, and p53 were also performed so that only pure CCC cases were included. PD-L1 (SP142), PD-1, and MMR antibodies were performed. PD-L1 and PD-1 were scored in both the tumor and the peritumoral lymphocyte infiltration. Clinical and pathological features were recorded to correlate with the expression of the 2 markers. Results. Among the 23 cases, 20 cases were qualified for pure CCC by histology and immunohistochemistry patterns. Regarding PD-1 expression, 6/20 (30%) patients had positive expression in peritumoral lymphocyte infiltration. While 3/20 (15%) cases had PD-L1 either tumoral or peritumoral lymphocytes expression. Loss of MMR expression was present in 1 (5%) of 20 patients. PD-1 and/or PD-L1 expression cases tended to have deeper myometrial invasion and higher stage at presentation. Conclusions. Our results are suggestive of the roles of both PD-1 and PD-L1 in ECCCs as useful therapeutic biomarkers for immunotherapy.

Clinical and pathological features of glycogen-rich clear cell carcinoma of the breast

Breast Cancer ◽  
2005 ◽  
Vol 12 (3) ◽  
pp. 189-195 ◽  
Author(s):  
Hajime Kuroda ◽  
Goi Sakamoto ◽  
Kiyoshi Ohnisi ◽  
Shinji Itoyama
Keyword(s):  
Cell Carcinoma ◽  
Clear Cell ◽  
Clear Cell Carcinoma ◽  
Pathological Features ◽  
Carcinoma Of The Breast ◽  
Clinical And Pathological Features

Renal Carcinoma in the Dog

1976 ◽  
Vol 13 (4) ◽  
pp. 264-276 ◽  
Author(s):  
V. M. Lucke ◽  
D. F. Kelly
Keyword(s):  
Weight Loss ◽  
Lymph Nodes ◽  
Cell Carcinoma ◽  
Renal Carcinoma ◽  
Clear Cell ◽  
Clear Cell Carcinoma ◽  
Pathological Features ◽  
Wide Range ◽  
Age Range ◽  
Clinical And Pathological Features

Thirty-three cases of canine renal carcinoma reported between 1907 and 1972 are reviewed, and clinical and pathological features of nine other cases seen in Bristol between 1966 and 1975 are described. Clinical features frequently include nonspecific signs of anorexia and weight loss. The age range of affected dogs varies from 3 to 15 years, with a mean of 7.1 years. Male dogs appear to be affected more frequently than females, but there is no breed predilection. The clinical behaviour of canine renal carcinoma is variable, with 4 years the longest survival time after nephrectomy. The primary tumours characteristically are large and unilateral and occupy most of one pole of a kidney. Metastatic spread can involve a wide range of organs, the commonest being lymph nodes and lung. Solid, tubular and papillary patterns are common. Clear cell carcinoma is uncommon.

scholarly journals Ovarian Seromucinous Borderline Tumor and Clear Cell Carcinoma: An Unusual Combination

2015 ◽  
Vol 2015 ◽  
pp. 1-5 ◽  
Author(s):  
Eriko Nakamura ◽  
Yuichiro Sato ◽  
Sayaka Moriguchi ◽  
Atsushi Yamashita ◽  
Takashi Higo ◽  
...  
Keyword(s):  
Cell Carcinoma ◽  
Tumor Cells ◽  
Clear Cell ◽  
Clear Cell Carcinoma ◽  
English Literature ◽  
Borderline Tumor ◽  
Borderline Tumors ◽  
First Case ◽  
Napsin A ◽  
Unusual Combination

Ovarian seromucinous borderline tumors (SMBTs) are rare. They architecturally resemble serous borderline tumors but are much more frequently associated with endometriosis. The coexistence of other tumors with seromucinous tumors is also extremely rare. Here, we report an unusual combination of bilateral ovarian SMBT and clear cell carcinoma associated with polypoid endometriosis of the colon, in a 62-year-old woman. There was no transitional lesion between the two tumors. Immunohistochemistry showed different staining patterns in tumor components. Seromucinous tumor cells were positive for estrogen receptor (ER) and progesterone receptor (PgR) but negative for Napsin A, p504S, and HNF1B. Clear cell tumor cells were positive for Napsin A and p504S and focally positive for HNF1B but negative for ER and PgR. Loss of ARID1A expression was not observed in SMBTs, clear cell tumors, or endometriosis. These findings suggest that these tumors arose from separate endometriosis foci and collided within the same ovary. To the best of our knowledge, this is the first case of this unusual combination of ovarian seromucinous tumor and clear cell carcinoma to be reported in the English literature.

Frequent Expression of Napsin A in Clear Cell Carcinoma of the Endometrium

2014 ◽  
Vol 38 (2) ◽  
pp. 189-196 ◽  
Author(s):  
Oluwole Fadare ◽  
Mohamed M. Desouki ◽  
Katja Gwin ◽  
Krisztina Z. Hanley ◽  
Elke A. Jarboe ◽  
...  
Keyword(s):  
Cell Carcinoma ◽  
Clear Cell ◽  
Clear Cell Carcinoma ◽  
Napsin A

Comparative Use of Napsin A and Glypican 3 to Distinguish Endometrial Clear Cell from Serous and Endometrioid Carcinomas

2018 ◽  
Vol 28 (7) ◽  
pp. 1318-1324 ◽  
Author(s):  
Eirwen M. Miller ◽  
Joan Tymon-Rosario ◽  
Jaya Sunkara ◽  
Bryan E. Harmon ◽  
Rouzan G. Karabakhtsian ◽  
...  
Keyword(s):  
Cell Carcinoma ◽  
Clear Cell ◽  
Clear Cell Carcinoma ◽  
Medical Center ◽  
Diagnostic Tools ◽  
High Grade ◽  
Napsin A ◽  
Treatment Data ◽  
Endometrial Cancers ◽  
Immunohistochemical Profile

ObjectiveDiagnosis of endometrial clear cell carcinomas is difficult owing to the low reproducibility of histological cell type in high-grade endometrial cancers. Recently, immunoreactivity for napsin A and glypican 3 has been reported in clear cell cancers. We sought to evaluate the use of napsin A and glypican 3 staining to distinguish clear cell carcinoma from other high-grade endometrial cancers.Methods/MaterialsTwenty cases of pure and mixed endometrial clear cell carcinoma were extracted from the 2000–2014 archival material in the Departments of Obstetrics & Gynecology and Pathology at Montefiore Medical Center and compared to serous and grade 3 endometrioid controls. Representative sections were stained with monoclonal antibodies to napsin A and glypican 3. Immunostains were independently reviewed by 2 pathologists to assess frequency and pattern of staining. Charts were reviewed for clinicopathologic and treatment data.ResultsGranular cytoplasmic positivity for napsin A was observed in 70% of endometrial clear cell carcinomas; only 25% showed cytoplasmic or membranous glypican 3 positivity. No serous or high-grade endometrioid tumors stained for either marker. No cases of clear cell carcinoma that stained negative for napsin A stained positive for glypican 3. No difference in the immunohistochemical profile was found between pure and mixed clear cell carcinomas and between early- and advanced-stage clear cell carcinomas.ConclusionsNapsin A is a more sensitive marker for endometrial clear cell carcinoma than glypican 3. In histologically ambiguous cases, napsin A and glypican 3 may help distinguish clear cell carcinoma from other high-grade histologies. Further investigation of endometrial clear cell carcinoma is needed to identify additional diagnostic tools for this rare histology. Correlation of a unique immunohistochemical profile and clinical outcomes is necessary.

Sign in / Sign up

Export Citation Format

Share Document